Calcium-dependent protein kinases are potential targets for *Toxoplasma gondii* vaccine

*Toxoplasma gondii* belongs to the Apicomplexa phylum that caused a widespread zoonotic infection in wide range of intermediate hosts. Over one-third of the world's population are latently infected with *T. gondii* and carry it. The complex life cycle of *T. gondii* indicates the presence of a plurality of antigenic epitopes. During the recent years, continuous efforts of scientists have made precious advances to elucidate the different aspects of the cell and molecular biology of *T. gondii*. Despite of great progresses, the development of vaccine candidates for preventing of *T. gondii* infection in men and animals is still remains a challenge. The calcium-dependent protein kinases (CDPKs) belongs to the superfamily of kinases, which restricted to the apicomplexans, ciliates, and plants. It has been documented that they contribute several functions in the life cycle of *T. gondii* such as gliding motility, cell invasion, and egress as well as some other critical developmental processes. In current paper, we reviewed the recent progress concerning the development of CDPK-based vaccines against acute and chronic *T. gondii*.

**Keywords:** *Toxoplasma gondii*, Calcium-dependent protein kinase, Vaccines, Immunization, Adjuvant

**Introduction**

*Toxoplasma gondii* belongs to the Apicomplexa phylum that caused a widespread zoonotic infection in a wide range of intermediate hosts, including men, livestock, birds, marine mammals, and snakes [1-7]. More than one century ago, this protist was discovered from the spleen and liver smears of a north African rodent namely *Ctenodactylus gondii* [8]. Recent review papers have documented over one-third of people throughout the globe are latently infected with *T. gondii* and carry it [7,9,10].

The biologic stages and the main transmission routes of *T. gondii* are depicted in Fig. 1. Briefly, *Toxoplasma* has three infectious stages: sporozoites (in oocysts), tachyzoites (rapidly multiplying form), and bradyzoites (tissue cyst form). Tachyzoites as rapidly multiplying forms are the main reason of the acute phase of toxoplasmosis and responsible for a wide spectrum of clinical signs. Once a host becomes infected, the parasite can survive with complex mechanisms for the whole lifespan within tissue cysts located usually in the skeletal muscles, brain, eyes, and myocardium. In some circumstances, particularly upon the suppression of immune system, latent encysted parasites can reactivate and the symptoms of infection became evident [11,12].
Toxoplasmosis predominantly is asymptomatic in immunocompetent persons, while may cause severe complications with life-threatening outcomes in immunosuppressed persons such as human immunodeficiency virus/acquired immune deficiency syndrome subjects, patients with malignancy and transplant recipients [3,10,13-15]. Upon maternal infection, fetus is probably to be exposed with vertical transmission, which may cause abortion in those pregnant women that acquired toxoplasmosis during her pregnancy. Notably, the complications will be differ according to the gestational age ranged from retardation, microcephaly, hydrocephalus, brain focal lesions, deafness, so on [16-19].
other hand, this unicellular protozoan parasite may result in fetal death, neonatal loss, and abortion in domestic animals, especially in goats and sheep which imposes heavy economic losses in the industry of veterinary medicine and animal husbandry. Furthermore, they serve as a source of transmission to humans [3,21]. Interestingly, it has been shown chronic toxoplasmosis considerably associated with some autoimmune diseases, mental and neurodegenerative disorders. In addition, the scientists frequently have confirmed that T. gondii infection can manipulate and alter the behavior, not only in animal models, but in men as well [22-26].

### Vaccine Candidate: Current State and Future

The present common primary control measures for men and animals T. gondii infection depends on chemotherapy. The drugs are not sufficiently satisfactory due to their side effects. For example, many concerns remain regarding the use of these medications in pregnant women because of the probable teratogenic effect on the fetus [27]. Besides, the routinely prescribed therapeutic medicines for the treatment of toxoplasmosis, can limit the proliferation of tachyzoites in the onset of infection, while they are unable to eliminate them and have no effect on the encysted parasites within infected hosts [27]. Hence, discover and development of an effective vaccine has high priority and urgently needed to prevent and control toxoplasmosis, because of the heavy burden of chronic infection throughout the world in different host species, particularly in men and domestic animals. For this reasons, several vaccine types with different approaches have been experimentally evaluated worldwide [28-36].

During three recent decades, continuous efforts of researchers have made precious successes in the development of T. gondii candidate vaccines mainly on dense granule antigens, microneme antigens, rhoptry antigens (ROP), and surface antigens. These vaccines predominantly induced partial protection along with reduction of brain cyst load post challenge with virulent and/or avirulent T. gondii strains in mouse models [30-33,37]. Currently, there is a commercially licensed vaccine known as Toxovax (the live-attenuated tachyzoites of T. gondii S48 strain) which used in the veterinary industry in some countries [38]. Toxovax reduces the incidence of congenital toxoplasmosis in sheep; however, it is not useful for human vaccination, particularly in immunosuppressed subjects, because of its reversion to the wild-type virulence as previously the accidental infections have been reported in farmers [28,31,33].

In regard to the major transmission routes of parasite and the toxoplasmosis manifestations in high risk groups, the main targets for vaccination strategy would cover [29,39]:

- Vaccination to prevent acute parasitemia and protect against congenital toxoplasmosis
- Prevent or reduce tissue cysts in food animals to interrupt the transmission route to humans
- Prevention or reduction of oocyst shedding in cats to confine environmental contamination as well as minimize the risk of toxoplasmosis for all intermediate hosts

### Calcium-Dependent Protein Kinase

The increasing number of experiments over the past decade has focused on the evaluation of the immunogenicity of main functional proteins including kinases and enzymes. These functional proteins, mainly involve in the duplication, transcription, metabolism, signaling pathways and other biological procedures of the parasite life cycle [40-47]. Based on genomic analysis, T. gondii encoded 108 protein kinases (presumably with a catalytic activity) and 51 pseudokinases genes (due to the absence of a catalytic domain) [48]. As signaling mediators of calcium-related signaling cascades, the calcium-dependent protein kinases (CDPKs) are a distinct protein kinase family, which belongs to the superfamily of kinases [49-51]. CDPKs are restricted to the apicomplexans, ciliates, and plants. In apicomplexan, particularly T. gondii, several CDPKs (as the most crucial household proteins) have been characterized involving in a different array of functions in the life cycle of parasite, including gliding motility, cell invasion and egress as well as some other pivotal developmental processes [49,51,52]. CDPKs not expressed by mammals and fungi which indicates validated targets that can be exploited for a promising target vaccine candidate against toxoplasmosis and anti-T. gondii drugs [52-56]. Out of 14 CDPKs present in T. gondii, CDPK1, CDPK3, CDPK4, CDPK5, CDPK6, and CDPK7 are the only CDPKs which expressed and conserved in almost all apicomplexan parasites [49,57,58].

The specific features and main functions of some CDPKs have been embedded in Table 1.

It is well known that gene knockouts of CDPKs may affect on specific developmental stages [49]. For instance, Billker et al. [59] showed the disruption of CDPK4 in asexual stages of Plasmodium berghei leads to differentiation defects in male gametocytes. They concluded “CDPK4 is essential for the
sexual reproduction and mosquito transmission of *P. berghei*. Furthermore, it has been shown conditional suppression of CDPK1 protein lead to loss of some capabilities, including parasite motility, host cell invasion, and egress [60]. The *T. gondii* kinase CDPK2 has functional Ca^{2+} and carbohydrate-binding domains, which its deficiency causes hyperaccumulation of starch in *Toxoplasma* parasites results death of chronic-stage parasites [47]. In another study, Morlon-Guyot et al. [57] reported that the downregulation of CDPK7 protein in *T. gondii* results in pronounced defects in parasite division and a major growth deficiency. The polarity of daughter cells budding and the fate of several subcellular structures or proteins involved in cell division were affected, as well. The authors have remarked “CDPK7 is crucial for proper maintenance of centrosome integrity required for the initiation of endodyogeny” [57]. More recently, Wang and colleagues assessed the functions of six different CDPKs including CDPK4, CDPK4A, CDPK5, CDPK6, CDPK8, and CDPK9 in *T. gondii* to determine are they suitable for designing as drug targets or not? For this purpose, clustered regularly interspaced short palindromic repeats/Cas9 system was employed to disrupt the CDPKs genes by insertion of dihydrofolate reductase and ultimately the six knockout (KO)-CDPK strains were successfully identified by indirect immunofluorescence. The findings revealed a lack of considerable difference between the six KO-CDPK strains and wild-type strain in virulence and the lytic cycle in terms of invasion, egress, and replication. The authors have highlighted “these CDPKs seems not pivotal for parasite lytic cycle and also not virulence factors for mice, probably they contribute in other functions of parasite [61].

**CDPK DNA Vaccine**

DNA vaccination as a robust method have become a major focus with many advantages compared to traditional vaccines in several parameters as follows [62-64]:

- Design (more rapid design as well as can be rapidly isolated and cloned)
- Versatility (ease in adapting or improving plasmid sequence, capability to deliver multi-antigen vaccines into a host only with a single dose, ease in formulation with different adjuvants)
- Production (cost effective, ease of production, capable of large-scale production, appropriate protein folding for correct epitope expression)
- Transport (stability at room temperature and no need to cold chain)
- Safety (cannot revert to the pathogenic form, safer than live or attenuated vaccines)
- Immune responses (boost the expression of an encoded vaccine antigen within host cells, able to induce a long-lasting immunity, elicits efficient and specific humoral and cellular immune responses, provide immune priming but poor immune boosting)

DNA vaccination recruits the plasmid vector in order to transfer and expression of the target gene and strongly elicit specific humoral and cell-mediated immune responses [34,62]. After the inoculation, the DNA enter to the cell cytoplasm then express the encoded protein target inside the host cell [62]. In general, during the course of toxoplasmosis both cell-mediated and humoral immune responses are elicited, so that the secretion of anti-\( \text{T. gondii} \) specific antibodies hamper the attachment of parasites to related host cell receptors. Furthermore, the specific-IgG antibodies have a critical role in restriction of toxoplasmosis through activation of the cellular complement cascades, enhancement of killing activity of macrophages to eliminate the intracellular parasites and other roles against this opportunistic agent [69]. Besides, the production of interferon-\( \gamma \) (IFN-\( \gamma \)) as the adaptive cellular immunity, limit the growth of \( \text{T. gondii} \) in different infection stages [70,71]. Notably, protection against \( \text{T. gondii} \) infection predominantly is developed through both types of CD8\(^+\) and CD4\(^+\) T cells as cell-mediated immunity arms. Although, as it is well established CD8\(^+\) T cell and IFN-\( \gamma \) are obvious to be more fundamental to restrict toxoplasmosis [33]. Recently, it has been shown that DNA vaccination with CDPK1, CDPK2, CDPK3, and CDPK5 dramatically increased the number of CD4\(^+\) and/or CD8\(^+\) T cells in immunized mice [52,54-56,58].

There are several limitations affecting the immune efficacy of DNA vaccines, which occasionally confined the immunogenicity of them such as dosages of inoculum and the delivery route [62]; however, 100 \( \mu \)g of the plasmid are routinely injected intramuscularly in mice [52,54-56,58]. It should be noted, following the inoculation, the naked DNA poorly distributed and rapidly degraded by lysosomes and DNAses, thereby, reduce the expression of plasmid DNA [72-74]. Thus, the use of adjuvants as a robust strategy has become popular because of the following reasons [62,63,74,75]:

- Augment the immunogenicity of DNA vaccines
- Boost DNA delivery
- Increased the magnitude/duration of plasmid DNA expression
- Recruit the immune cells to the site of inoculation, thereby increases the immunostimulatory features of plasmid
- Help the uptake of DNA into host cells or by professional antigen-presenting cells (APCs)
- Protect plasmid against degradation by DNAses

An increasing number of papers have demonstrated that the use of genetic adjuvants such as cytokines (IFN-\( \gamma \), interleukin [IL]-7, IL-12, IL-15, IL18, IL-21, etc.), chemokines, co-stimulatory molecules (B7-1, B7-2, etc.), etc. strongly augment the protective efficacy of DNA vaccine [33,34,54,56,76-79]. Genetic adjuvants can be either encoded on a separate vector, or expressed on the same vector as the antigen and thereafter co-administrated with the vaccine [34,62,63,75].

CDPK1 as an essential regulator of calcium-dependent exocytosis in \( \text{T. gondii} \) is conserved between both type I and type II \( \text{T. gondii} \) strains which expressed in the bradyzoite and tachyzoite stages [56,60]. TgCDPK1 was localized in the cytoplasm, but also found in the nucleus [65]. It has been shown that Kunming mice immunized with pVAX-CDPK1 survived for a significant longer time post intraperitoneally challenge with 1 \( \times \) 10\(^3\) tachyzoites of RH strain. Also, the immunized mice showed a mixed Th1/Th2 response with the predominance of IgG2a levels over IgG1, increased secretion of IFN-\( \gamma \), IL-2, IL-4, and IL-10 cytokines, enhanced splenocyte proliferation and percentages of CD4\(^+\) and CD8\(^+\) T cells as well as reduction of brain cyst load, compared with control groups (p<0.05) [54,56]. Notably, co-delivery of pVAX/IL-21/IL-15 or pVAX/IL-7/IL-15 plus pVAX-CDPK1 considerably boosted the above-mentioned outcomes in mice (p<0.05) [54,56]. The co-injection of plasmids encoding cytokine is one the best approaches to boost the efficiency of DNA vaccines that has several advantages, including ease of cloning process, simplicity, and cost benefits [63]. For instance, IL-7 and IL-15 are dominantly involved in the generation and homeostasis of memory T cells [80]. Besides, it is well established that signaling by both IL-7 and IL-15 cytokines could synergize to boost the generation of memory T cells [81]. As common g chain cytokines, including IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21, recent papers have reported co-administration of pVAX/IL-21/IL-15 plus pVAX-MIC8 or pVAX-CDPK1 promoted protective immunity of DNA vaccines expressing MIC8 and CDPK1 [56,82]. More examples of immunization experiments with DNA vaccines against \( \text{T. gondii} \)
### Table 2. Baseline characteristics of included studies based on immunization experiments with DNA or protein vaccines against *Toxoplasma gondii* in mouse models

| Antigen | Adjuvant or carrier | Ag delivery | Mouse strain | Challenge | Immune responses | Brain cyst load | Survival | Reference |
|---------|---------------------|-------------|--------------|-----------|-----------------|----------------|----------|-----------|
| CDPK1   | IL-15 and IL-21     | Plasmid, i.m. | Kunming      | Acute: 1×10⁶ tachyzoites, RH strain, i.p. Chronic: 20 cysts of the PRU strain, orally | Induced a strong IgG antibody response (p<0.05) The levels of IgG antibody in the pVAX-CDPK1+pVAX/IL-21/IL-15 group was significantly higher than that with pVAX-CDPK1 alone (p<0.05) Mixed IgG1/IgG2a response with the predominance of IgG2a over IgG1 Higher levels of IgG2a and IgG1 in mice immunized with pVAX-CDPK1+pVAX/IL-21/IL-15 compared with pVAX-CDPK1 group (p<0.05) ↑ Splenocyte proliferation significantly in the groups immunized with pVAX-CDPK1 or pVAX-CDPK1+pVAX/IL-21/IL-15 (especially in the latter group) ↑ IFN-γ, IL-2, IL-4, and IL-10 (especially in the pVAX-CDPK1+pVAX/IL-21/IL-15 group, p<0.05) ↑ Percentages of CD4⁺ T and CD8⁺ cells (p<0.05) | Reduced pVAX-CDPK1: 45.7% (p<0.05) pVAX-CDPK1+pVAX/IL-21/IL-15: 72.7% (p<0.05) | Increased survival time pVAX-CDPK1: 17.3±4.3 days (p<0.05) pVAX-CDPK1+pVAX/IL-21/IL-15: 19.2±5.1 days (p<0.05) | All control mice died within 6 days |
| IL-7 and IL-15 | Plasmid, i.m. | Acute: 1×10⁶ tachyzoites, RH strain, i.p. Chronic: 10 cysts of the PRU strain, orally | Kunming | Induced a strong IgG antibody response (p<0.05) The levels of IgG antibody in the pVAX-CDPK1+pVAX/IL-7/IL-15 group was significantly higher than that with pVAX-CDPK1 alone (p<0.05) Mixed IgG1/IgG2a response with the predominance of IgG2a over IgG1 ↑ Splenocyte proliferation significantly in the groups immunized with pVAX-CDPK1 or pVAX-CDPK1+pVAX/IL-7/IL-15 (especially in the latter group) ↑ IFN-γ, IL-2, IL-4, and IL-10 (especially in the pVAX-CDPK1+pVAX/IL-7/IL-15 group, p<0.05) ↑ Percentages of CD4⁺ T and CD8⁺ cells (p<0.05) | Reduced pVAX-CDPK1: 46% (p<0.05) pVAX-CDPK1+pVAX/IL-7/IL-15: 73.5% (p<0.05) | Increased survival time pVAX-CDPK1: 14.13±3.85 days (p<0.05) pVAX-CDPK1+pVAX/IL-7/IL-15: 18.07±5.43 days (p<0.05) | All control mice died within 9 days |
| CDPK2   | -                   | Plasmid, i.m. | BALB/c       | 1×10⁶ tachyzoites, RH strain, i.p. | Induced a strong IgG antibody response (p<0.05) Mixed IgG1/IgG2a response with the predominance of IgG2a over IgG1 ↑ Proliferation SI (1.76±0.24, p<0.05) ↑ Percentages of CD4⁺ T and CD8⁺ cells (p<0.05) ↑ IFN-γ (864.56±76.72 pg/mL, p<0.05), IL-12 p-70 (334.51±7.52 pg/mL, p<0.05), and IL-10 (421±23.25 pg/mL, p<0.05) Similar levels of IL-4 between the different immunized and unimmunized groups (p>0.05) | Reduced (p<0.05) | Increased survival time (14±2.32 days, p<0.05) All control mice died within 8 days |
| CDPK3   | -                   | Plasmid, i.m. | Kunming      | Acute: 1×10⁶ tachyzoites, RH strain, i.p. Chronic: 10 cysts of the PRU strain, orally | Induced a strong IgG antibody response (p<0.05) Mixed IgG1/IgG2a response with the predominance of IgG2a over IgG1 ↑ Proliferation SI (1.30±0.18, p<0.05) ↑ Percentages of CD4⁺ T cells (p<0.05) ↑ IFN-γ (812.11±128.56 pg/mL, p<0.05), IL-2 (263.79±35.43 pg/mL, p<0.05), IL-12 p-70 (129.63±77.42 pg/mL, p<0.05), IL-4 (32.42±2.74 pg/mL, p<0.05), IL-10 (870.12±226.50 pg/mL, p<0.05), and IL-23 (87.59±7.14 pg/mL, p<0.05) | Reduced (p<0.05) | Increased survival time (13.5±4.89 days, p<0.05) | [58] |

(Continued to the next page)
| Antigen     | Adjuvant or carrier | Ag delivery | Mouse strain | Challenge                                                                 | Immune responses                                                                                      | Brain cyst load                  | Survival                  | Reference |
|------------|---------------------|-------------|--------------|--------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------|----------------------------------|---------------------------|-----------|
| CDPK5      | -                   | Plasmid, i.m. | Kunming      | Acute: 1×10³ tachyzoites, RH strain, i.p.                               | Induced a strong IgG antibody response (p < 0.05)                                                   | Reduced (39.13%, p = 0.005)       | Prolonged survival time, but the difference was not statistically significant (8.67±4.34 days, p > 0.05) | [55]      |
|            |                     |             |              | Chronic: 10 cysts of the PRU strain, orally                           | Mixed IgG1/IgG2a response with the predominance of IgG2a over IgG1                                 |                                  |                           |           |
|            |                     |             |              |                                                                          | ↑ Proliferation SI (1.92±0.07, p < 0.001)                                                              |                                  |                           |           |
|            |                     |             |              |                                                                          |↑ Percentages of CD4⁺ T and CD8⁺ cells (p = 0.04)                                                      |                                  |                           |           |
|            |                     |             |              |                                                                          | ↑ IFN-γ (982.68±378.22 pg/mL, p < 0.05), IL-2 (266.04±9.13 pg/mL, p < 0.05), IL-12 p-70 (66.84±4.06 pg/mL, p < 0.05), and IL-10 (136.53±71.63 pg/mL, p < 0.05) |                                  |                           |           |
|            |                     |             |              |                                                                          | ↑ IFN-γ (982.68±378.22 pg/mL, p < 0.05), IL-2 (266.04±9.13 pg/mL, p < 0.05), IL-12 p-70 (66.84±4.06 pg/mL, p < 0.05), and IL-10 (136.53±71.63 pg/mL, p < 0.05) |                                  |                           |           |
|            |                     |             |              |                                                                          | ↑ IFN-γ (982.68±378.22 pg/mL, p < 0.05), IL-2 (266.04±9.13 pg/mL, p < 0.05), IL-12 p-70 (66.84±4.06 pg/mL, p < 0.05), and IL-10 (136.53±71.63 pg/mL, p < 0.05) |                                  |                           |           |
|            |                     |             |              |                                                                          |↑ Percentages of CD4⁺ and CD8⁺ cells in mice immunized with the various protein vaccines and PLG microparticles, compared with controls |                                  |                           |           |
|            |                     |             |              |                                                                          |↑ Percentages of CD4⁺ cells in mice immunized with rROP18+206 and rROP18+PLG, compared with controls |                                  |                           |           |
|            |                     |             |              |                                                                          | ↑ IFN-γ and IL-2 significantly in the mice immunized with various proteins, compared with the control groups |                                  |                           |           |
|            |                     |             |              |                                                                          |↓ IL-4 and IL-10, compared with the control groups (p < 0.05)                                        |                                  |                           |           |
|            |                     |             |              |                                                                          | Similar levels of IL-12 between vaccinated and control groups (p > 0.05). Induced Th1-biased immune responses |                                  |                           |           |
| CDPK6+ROP18 | Montanide™ ISA 206 VG (206) and PLG | s.c.         | Kunming      | Acute: 1×10³ tachyzoites, RH strain, i.p.                               | ↑ Specific IgG antibody responses in the mice immunized with rROP18+PLG or rCDPK6+rROP18+PLG       | Reduced (varied from 47.7% to 73.6%, p < 0.001) | Increased survival time of the mice immunized with the various protein vaccines (8.56 days) was slightly longer than that in the controls (8 days) | [53]      |
| Main groups: |                     |             |              | Chronic: 10 cysts of the PRU strain (type II), orally                   | ↑ Splenocyte proliferation significantly (highest in mice immunized with rCDPK6+rROP18+PLG, p < 0.001), compared with the control groups |                                  |                           |           |
| PBS        |                     |             |              |                                                                          | ↑ CD4⁺ and CD8⁺ T cells in mice immunized with various protein vaccines and PLG microparticles, compared with controls |                                  |                           |           |
| rROP18     |                     |             |              |                                                                          | ↑ Levels of CD4⁺ (p < 0.001) and CD8⁺ T lymphocytes (p < 0.01) in mice immunized with protein–PLG microparticles, compared with controls |                                  |                           |           |
| rROP18+206 |                     |             |              |                                                                          | ↑ Percentages of CD4⁺ cells in mice immunized with rROP18+206 and rROP18+PLG, compared with controls (p < 0.05) |                                  |                           |           |
| rROP18+206 |                     |             |              |                                                                          | ↑ IFN-γ and IL-2 significantly in the mice immunized with various proteins, compared with the control groups |                                  |                           |           |
| rROP18+PLG |                     |             |              |                                                                          |↓ IL-4 and IL-10, compared with the control groups (p < 0.05)                                        |                                  |                           |           |
| rROP18+CDPK6+PLG |                     |             |              |                                                                          | Similar levels of IL-12 between vaccinated and control groups (p > 0.05). Induced Th1-biased immune responses |                                  |                           |           |

CDPK, calcium-dependent protein kinase; IL, interleukin; i.m., intramuscular; i.p, intraperitoneally; ↑, increase; ↓, decrease; IFN-γ, interferon-γ; SI, stimulation index; NR, not reported; PBS, phosphate-buffered saline; ROP, rhoptry antigen; PLG, polylactide-co-glycolide.
Recombinant CDPK Protein Vaccine

During recent decades, continuous attempts of researchers have revealed great achievements to clarify the different perspectives of the cell and molecular biology of *T. gondii* [49,57, 60,67,68,83-86]. These efforts resulted great motivation in the current focus on vaccine development against chronic and acute toxoplasmosis, based on the distinctive subcellular components of the parasite [28-32,34]. Recombinant subunit vaccines provide an alternative way for the development of vaccine candidates in both animals and men. These vaccine types can induce humoral and cellular immune responses as well as they are very suitable for large-scale production [30,31]. Application of traditional and genetic adjuvants has become popular, due to their potential capability in augmenting specific and long-lasting protective immunity [75,87].

Owing to proteolytically degradation of recombinant proteins, presence of a proper delivery system is necessary to protect them from degradation [88]. Polylactide-co-glycolide (PLG) is a biodegradable and biocompatible polymer which extend the protein releasing period to induce a long-lasting immune response as well as reduce the protein degradation. Besides, PLG by increasing the uptake of antigen and its presentation by APCs would augment the protective immunity. This biodegradable polymer encapsulates the recombinant subunit vaccines, which maintain their antigenicity to boost the efficacy [53,89]. In this context, Zhang et al. (2016) [53] designed a comprehensive study on two recombinant proteins rROP18 and rCDPK6 adjuvanted with PLG and Montanide ISA 206 VG (206). In brief, the mice were vaccinated subcutaneously with different proteins (with or without adjuvant) and then challenged intraperitoneally with $1 \times 10^3$ tachyzoites of RH strain (type I) and orally with 10 cysts of the PRU strain (type II) for acute and chronic infection, respectively. The findings revealed both recombinant protein vaccines promoted specific humoral and cellular Th1-biased immune responses, high production of IFN-$\gamma$ and IL-2 cytokines with strong lymphocyte proliferative responses. The titers of IgG values in Kunming mice vaccinated with rROP18+PLG or rCDPK6+ rROP18+PLG were dramatically higher than rROP18 or rCDPK6+ rROP18 (p<0.01) groups, however, were not dramatically different from those mice injected with various proteins-montanide 206 adjuvant (p>0.05). Also, the highest splenocyte proliferative responses were observed in the mice vaccinated with rROP18+rCDPK6+ PLG (p<0.001). Moreover, increased percentage of CD4+ and CD8+ T cells were recorded in mice immunized with the various protein vaccines (especially in protein–PLG groups). The brain tissue cyst burden in mice immunized with the various proteins was significantly reduced than those in control groups (p<0.001), ranging from 47.7% to 73.6%. The authors concluded that “the use of PLG is superior than Montanide 206, because of encapsulated proteins into PLG conferred immunity to *T. gondii* for an extended period. However, evaluation of the potency of PLG in the development of a vaccine against toxoplasmosis should be further studied in future” [53]. More details can be found in Table 2. Application of PLG on other antigens frequently have been tested and showed acceptable outcomes [90-92]. For instance, rROP18 encapsulated in nanoparticles with polylactide-co-glycolide acid (rROP18+PLGA), significantly increased the values of IgG antibody, elicited Th1-type responses with the predominance of IgG2a over IgG1, and enhanced intestinal IgA values [91]. In another investigation, rROP18 and rROP38 encapsulated into PLG elicited both humoral and cell-mediated immune responses in Kunming mice in terms of total IgG titers (p<0.01), IgG2a subclass (p<0.01), IFN-$\gamma$ cytokine (p<0.01) and mixed Th1/Th2 immunity responses (but bias to Th1). Also, the formulation of mixed antigens (rROP38+rROP18+PLG) boosted the efficacy of vaccine [90]. The above findings suggest that PLG could be a promising novel adjuvant with preserving the protein immunogenicity for longer duration.

CDPK Peptide Vaccine

More recently, bioinformatics as a novel interdisciplinary science has become favorite which analyze the biological data using defined technologies and algorithms from computer sciences, mathematics, statistics, physics, biology, and medicine [93]. This new science has several advantages in comparison to traditional methods such as satisfactory precision and accuracy, relatively inexpensive and affordable, etc. Nowadays, Bioinformatics is extensively used to predict protein structures, biological characteristics, functions, epitopes, and design of new vaccines [93-95]. The prediction of epitopes is highly fundamental to assess the immunogenicity of an antigen in design of reverse vaccines. Accordingly, bioinformatics softwares and online databases could help scientists to predict and recognize the potential B and T cell epitopes [93,95,96]. In this regards, Zhang et al. (2014) [66] designed an investiga-
tion using multiple Bioinformatics approaches on TgCDPK6 protein to identify potential antigenicity, signal peptides, topological structures, epitopes, and other chemical and physical characteristics. They showed 26 post-translational modification sites in the protein. In addition, the secondary structure of CDPK6 showed that nearly 58% of its amino acids are exposed to the solvent interface. The prediction of functional domains revealed TgCDPK6 possess seven protein kinase C phosphorylation sites and one protein kinase adenosine triphosphate (ATP)-binding region. In the other hand, the high hydrophilic domains were distributed in amino acid positions 21-59, 68-81, 156-205, 245-271, 280-294, 297-324, 334-356, 367-393, 474-498, and 543-553. The advanced structure of TgCDPK6 was developed by a homology modeling method and then validated by PROCHECK, represented that most amino acid residues were in the most favored regions. In the study, ten potential epitopes were recognized. The authors have concluded that “TgCDPK6 could be a highly potent DNA vaccine candidate against T. gondii; however, more experimentally studies are needed in future” [66]. It should be noted, a recent study by the same authors from the same lab demonstrated satisfactory outcomes following vaccination of Kunming mice with the formulation of rCDPK6+rROP18+PLG [53].

There is a lack of study regarding epitope-based vaccines on CDPKs. Previously was shown that multi-epitope-based vaccines, strongly elicited both humoral and cellular immune responses, thereby significantly prolonged survival time along with reduction of brain cyst burden in immunized mice [97-100]. Multi-epitope-based vaccines, carry the potential B and T cell epitopes simultaneously that relevant with the targeted antigens or helper epitopes. Also, these vaccines with reduction of undesirable factors lead to improve the highly specific responses and better protection [95,98].

Conclusion

T. gondii can infect a wide spectrum of warm-blooded vertebrate species. Toxoplasmosis predominantly is asymptomatic in normal persons, while may display severe complications with life-threatening outcomes in immunocompromised individuals. Since current drugs have no effect on the encysted parasites, thus, discover of an appropriate vaccine has high priority and urgently required to prevent and control toxoplasmosis, because of the heavy burden of chronic infection worldwide. The use of DNA vaccines expressing CDPK1, CDPK3, and CDPK5, prolonged the survival time as well as reduced the percentage of brain tissue cysts (up to 73.5% reduction) in mice. Nevertheless, these experiments failed to show complete protection (Table 2). The use of live-attenuated vectors as vehicles and prime-boost regimens are other powerful strategies in vaccine design studies which should be paid more attention in future investigations. The complex life cycle of T. gondii indicates the presence of a plurality of antigenic epitopes. As confirmed earlier, vaccination with stage-specific antigens often lead to stage-limited protection. Hence, those antigens that are expressed in various stages of Toxoplasma life cycles, confers more protective immunity against parasite infection [95,101]. Since the immunogenicity of the predicted sequences by bioinformatics softwares should be confirmed in suitable animal models, thus, design of investigations with both in vivo and in silico methods is highly recommended to assess the potency of vaccine candidates for the future. Collectively, valuable finding has been gained that gives promising perspectives. Notably, various limitations may affect the outcomes of vaccine studies, including inadequate evaluation criteria, unsuitable vaccination protocol, the strain of T. gondii, the vaccine constructs, the delivery route, dosage of inoculum, various mouse models, and so on. The future surveys must be covered all above mentioned aspects to minimize the faults. Besides, optimized vaccination protocol and use of different types of delivery systems, genetic and/or non-genetic adjuvants undoubtedly would influence the results.

ORCID

Masoud Foroutan  http://orcid.org/0000-0002-8661-7217
Fatemeh Ghaffarifar  http://orcid.org/0000-0003-0891-8214

References

1. Nasiri V, Teymurzadeh S, Karimi G, Nasiri M. Molecular detection of Toxoplasma gondii in snakes. Exp Parasitol 2016;169:102-6.
2. Dubey JP. The history of Toxoplasma gondii: the first 100 years. J Eukaryot Microbiol 2008;55:467-75.
3. Foroutan M, Dalvand S, Daryani A, et al. Rolling up the pieces of a puzzle: a systematic review and meta-analysis of the prevalence of toxoplasmosis in Iran. Alex J Med 2017 Jun 23 [Epub]. https://doi.org/10.4132/10.1016/j.ajme.2017.06.003.
4. Rostami A, Riahi SM, Fakhri Y, et al. The global seroprevalence of Toxoplasma gondii among wild boars: a system-
5. Khademvatan S, Foroutan M, Hazrati-Tappeh K, et al. Toxoplasmosis in rodents: a systematic review and meta-analysis in Iran. J Infect Public Health 2017;10:487-93.

6. Foroutan M, Majidiani H. Toxoplasma gondii: are there any implications for routine blood screening? Int J Infect 2017 Oc 31 [Epub], https://doi.org/10.5812/iji.62886.

7. Foroutan-Rad M, Majidiani H, Dalvand S, et al. Toxoplasmosis in blood donors: a systematic review and meta-analysis. Transfus Med Rev 2016;30:116-22.

8. Nicolle C, Manceaux L. Sur une infection à corps de Leishman (ou organismes voisins) du gondi. CR Acad Sci 1908; 147:763-6.

9. Pappas G, Roussos N, Falagas ME. Toxoplasmosis snapshots: global status of Toxoplasma gondii seroprevalence and implications for pregnancy and congenital toxoplasmosis. Int J Parasitol 2009;39:1385-94.

10. Wang ZD, Liu HH, Ma ZX, et al. Toxoplasma gondii infection in immunocompromised patients: a systematic review and meta-analysis. Front Microbiol 2017;8:389.

11. Sullivan WJ Jr, Jeffers V. Mechanisms of Toxoplasma gondii persistence and latency. FEMS Microbiol Rev 2012;36: 717-33.

12. Weiss LM, Dubey JP. Toxoplasmosis: a history of clinical observations. Int J Parasitol 2009;39:895-901.

13. Mohammadnejad F, Ghaffariar F, Mobedi I. HIV and parasite co-infection epidemiology: a scope since 2005. Rev Med Microbiol 2015;26:20-5.

14. Saki J, Khademvatan S, Soltani S, Shahbazian H. Detection of toxoplasmosis in patients with end-stage renal disease by enzyme-linked immunosorbent assay and polymerase chain reaction methods. Parasitol Res 2013;112:163-8.

15. Yousefi E, Foroutan M, Salehi R, Khademvatan S. Detection of acute and chronic toxoplasmosis amongst multi-transfused thalassemia patients in southwest of Iran. J Acute Dis 2017;6:120-5.

16. Saki J, Shafieenia S, Foroutan-Rad M. Seroprevalence of toxoplasmosis in diabetic pregnant women in southwestern of Iran. J Parasit Dis 2016;40:1586-9.

17. Foroutan-Rad M, Khademvatan S, Majidiani H, Aryamand S, Rahim F, Malehi AS. Seroprevalence of Toxoplasma gondii in the Iranian pregnant women: a systematic review and meta-analysis. Acta Trop 2016;158:160-9.

18. Abdoli A, Dalimi A, Soltanthorae H, Ghaffariar F. Molecular detection and genotypic characterization of Toxoplasma gondii in paraffin-embedded fetoplacental tissues of women with recurrent spontaneous abortion. Int J Fertil Steril 2017;10:327-36.

19. Fallahi S, Rostami A, Nouroollahpour Shaideh M, Behniasfar H, Pakatinat S. An updated literature review on maternal-fetal and reproductive disorders of Toxoplasma gondii infection. J Gynecol Obstet Hum Reprod 2017 Dec 8 [Epub], https://doi.org/10.1016/j.jogoh.2017.12.003.

20. Centers for Disease Control and Prevention (CDC). Toxoplasmosis [Internet]. Atlanta, GA: Centers for Disease Control and Prevention (CDC); 2017 [cited 2018 Jan 6]. Available from: https://www.cdc.gov/dpdx/toxoplasmosis/.

21. Shariif M, Sarvi S, Shokri A, et al. Toxoplasma gondii infection among sheep and goats in Iran: a systematic review and meta-analysis. Parasitol Res 2015;114:1-16.

22. Majidiani H, Dalvand S, Daryani A, Galvan-Ramirez ML, Foroutan-Rad M. Is chronic toxoplasmosis a risk factor for diabetes mellitus? A systematic review and meta-analysis of case-control studies. Braz J Infect Dis 2016;20:605-9.

23. Sutherland AL, Fond G, Kuin A, et al. Beyond the association. Toxoplasma gondii in schizophrenia, bipolar disorder, and addiction: systematic review and meta-analysis. Acta Psychiatr Scand 2015;132:161-79.

24. Flegr J. Neurological and neuropsychiatric consequences of chronic Toxoplasma infection. Curr Clin Microbiol Rev 2015;2:163-72.

25. Havlicek J, Gasova ZG, Smith AP, Zvara K, Flegr J. Decrease of psychomotor performance in subjects with latent ‘asymptomatic’ toxoplasmosis. Parasitology 2001;122(Pt 5): 515-20.

26. Webster JP, Brunton CF, MacDonald DW. Effect of Toxoplasma gondii upon neophobic behaviour in wild brown rats, Rattus norvegicus. Parasitology 1994;109(Pt 1):37-43.

27. Antczak M, Dzitko K, Dlugonska H. Human toxoplasmosis-searching for novel chemotherapeutics. Biomed Pharmacother 2016;82:677-84.

28. Hiszczynska-Sawicka E, Gatkowska JM, Grzybowski MM, Dlugonska H. Veterinary vaccines against toxoplasmosis. Parasitology 2014;141:1365-78.

29. Innes EA. Vaccination against Toxoplasma gondii: an increasing priority for collaborative research? Expert Rev Vaccines 2010;9:1117-9.

30. Kur J, Holec-Gasior L, Hiszczynska-Sawicka E. Current status of toxoplasmosis vaccine development. Expert Rev Vaccines 2009;8:791-808.

31. Garcia JL. Vaccination concepts against Toxoplasma gondii.
Masoud Foroutan et al • CDPK-based vaccines development against Toxoplasma gondii

dii. Expert Rev Vaccines 2009;8:215-25.
32. Lim SS, Othman RY. Recent advances in Toxoplasma gondii immunotherapeutics. Korean J Parasitol 2014;52:581-93.
33. Zhang NZ, Chen J, Wang M, Petersen E, Zhu XQ. Vaccines against Toxoplasma gondii: new developments and perspectives. Expert Rev Vaccines 2013;12:1287-99.
34. Ghaffarifar F. Strategies of DNA vaccines against toxoplasmosis. Rev Med Microbiol 2015;26:88-90.
35. Hoseinian Khosroshahi K, Ghaffarifar F, D’Souza S, Sharifi Z, Dalimi A. Evaluation of the immune response induced by DNA vaccine cocktail expressing complete SAG1 and ROP2 genes against toxoplasmosis. Vaccine 2011;29:778-83.
36. Naserifar R, Ghaffarifar F, Dalimi A, Sharifi Z, Solhjoo K, Hoseinian Khosroshahi K. Evaluation of immunogenicity of cocktail DNA vaccine containing plasmids encoding complete GRA5, SAG1, and ROP2 antigens of Toxoplasma gondii in BALB/C mice. Iran J Parasitol 2015;10:590-8.
37. Jongert E, Roberts CW, Gargano N, Forster-Waldl E, Petersen E. Vaccines against Toxoplasma gondii: challenges and opportunities. Mem Inst Oswaldo Cruz 2009;104:252-66.
38. Buxton D. Toxoplasmosis: the first commercial vaccine. Parasitol Today 1993;9:335-7.
39. Dlugonska H. Toxoplasma rhoptries: unique secretory organelles and source of promising vaccine proteins for immunoprevention of toxoplasmosis. J Biomed Biotechnol 2008;2008:632424.
40. Wang S, Hassan IA, Liu X, et al. Immunological changes induced by Toxoplasma gondii glutathione-S-transferase (TgGST) delivered as a DNA vaccine. Res Vet Sci 2015;99:157-64.
41. Hassan IA, Wang S, Xu L, Yan R, Song X, Li X. Immunoglobulin and cytokine changes induced following immunization with a DNA vaccine encoding Toxoplasma gondii aspartic protease 1 as a novel vaccine candidate against toxoplasmosis. Parasit Vectors 2013;6:175.
44. Gong P, Huang X, Yu Q, et al. The protective effect of a DNA vaccine encoding the Toxoplasma gondii cyclophilin gene in BALB/c mice. Parasite Immunol 2013;35:140-6.
45. Chen J, Huang SY, Zhou DH, et al. DNA immunization with eukaryotic initiation factor-2alpha of Toxoplasma gondii induces protective immunity against acute and chronic toxoplasmosis in mice. Vaccine 2013;31:6225-31.
46. Chen J, Huang SY, Li ZY, et al. Protective immunity induced by a DNA vaccine expressing eIF4A of Toxoplasma gondii against acute toxoplasmosis in mice. Vaccine 2013;31:1734-9.
47. Uboldi AD, McCoy JM, Blume M, et al. Regulation of starch stores by a Ca(2+)-dependent protein kinase is essential for viable cyst development in Toxoplasma gondii. Cell Host Microbe 2015;18:670-81.
48. Peixoto L, Chen F, Harb OS, et al. Integrative genomic approaches highlight a family of parasite-specific kinases that regulate host responses. Cell Host Microbe 2010;8:208-18.
49. Billker O, Lourido S, Sibley LD. Calcium-dependent signaling and kinases in apicomplexan parasites. Cell Host Microbe 2009;5:612-22.
50. Nagamune K, Sibley LD. Comparative genomic and phylogenetic analyses of calcium ATPases and calcium-regulated proteins in the apicomplexa. Mol Biol Evol 2006;23:1613-27.
51. Moreno SN, Docampo R. Calcium regulation in protozoan parasites. Curr Opin Microbiol 2003;6:359-64.
52. Zhang NZ, Huang SY, Zhou DH, et al. Protective immunity against Toxoplasma gondii induced by DNA immunization with the gene encoding a novel vaccine candidate: calcium-dependent protein kinase 3. BMC Infect Dis 2013;13:512.
53. Zhang NZ, Xu Y, Wang M, et al. Vaccination with Toxoplasma gondii calcium-dependent protein kinase 6 and rhoptry protein 18 encapsulated in poly(lactide-co-glycolide) microspheres induces long-term protective immunity in mice. BMC Infect Dis 2016;16:168.
54. Chen J, Li ZY, Petersen E, Liu WG, Zhu XQ. Co-administration of interleukins 7 and 15 with DNA vaccine improves protective immunity against Toxoplasma gondii. Exp Parasitol 2016;162:18-23.
55. Zhang NZ, Huang SY, Xu Y, et al. Evaluation of immune responses in mice after DNA immunization with putative Toxoplasma gondii calcium-dependent protein kinase 5. Clin Vaccine Immunol 2014;21:924-9.
56. Chen J, Li ZY, Huang SY, et al. Protective efficacy of Toxoplasma gondii calcium-dependent protein kinase 1 (TgCDPK1) adjuvanted with recombinant IL-15 and IL-21 against
experimental toxoplasmosis in mice. BMC Infect Dis 2014; 14:487.

57. Morlon-Guyot J, Berry L, Chen CT, Gubbels MJ, Lebrun M, Daher W. The Toxoplasma gondii calcium-dependent protein kinase 7 is involved in early steps of parasite division and is crucial for parasite survival. Cell Microbiol 2014; 16:95-114.

58. Chen K, Wang JL, Huang SY, Yang WB, Zhu WN, Zhu XQ. Immune responses and protection after DNA vaccination against Toxoplasma gondii calcium-dependent protein kinase 2 (TgCDPK2). Parasite 2017;24:41.

59. Billker O, Dechamps S, Tewari R, Wenig G, Franke-Fayard B, Brinkmann V. Calcium and a calcium-dependent protein kinase regulate gamete formation and mosquito transmission in a malaria parasite. Cell 2004;117:503-14.

60. Lourido S, Shuman J, Zhang C, Shokat KM, Hui R, Sibley LD. Calcium-dependent protein kinase 1 is an essential regulator of exocytosis in Toxoplasma. Nature 2010;465:359-62.

61. Wang JL, Huang SY, Li TT, Chen K, Ning HR, Zhu XQ. Evaluation of the basic functions of six calcium-dependent protein kinases in Toxoplasma gondii using CRISPR-Cas9 system. Parasitol Res 2016;115:697-702.

62. Li L, Petrovsky N. Molecular mechanisms for enhanced DNA vaccine immunogenicity. Expert Rev Vaccines 2016; 15:313-29.

63. Saade F, Petrovsky N. Technologies for enhanced efficacy of DNA vaccines. Expert Rev Vaccines 2012;11:189-209.

64. Doria-Rose NA, Haigwood NL. DNA vaccine strategies: candidates for immune modulation and immunization regimens. Methods 2003;31:207-16.

65. Ojo KK, Larson ET, Keyloun KR, et al. Toxoplasma gondii calcium-dependent protein kinase 1 is a target for selective kinase inhibitors. Nat Struct Mol Biol 2010;17:602-7.

66. Zhang NZ, Huang SY, Zhou DH, Xu Y, He JJ, Zhu XQ. Identification and bioinformatic analysis of a putative calcium-dependent protein kinase (CDPK6) from Toxoplasma gondii. Genet Mol Res 2014;13:10669-77.

67. McCoy JM, Whitehead L, van Dooren GG, Tonkin CJ. TgCDPK3 regulates calcium-dependent egress of Toxoplasma gondii from host cells. PLoS Pathog 2012;8:e1003066.

68. Garrison E, Treeck M, Ehret E, et al. A forward genetic screen reveals that calcium-dependent protein kinase 3 regulates egress in Toxoplasma. PLoS Pathog 2012;8:e1003049.

69. Sayles PC, Gibson GW, Johnson LL. B cells are essential for vaccination-induced resistance to virulent Toxoplasma gondii. Infect Immun 2000;68:1026-33.

70. Denkers EY, Gazzinelli RT. Regulation and function of T-cell-mediated immunity during Toxoplasma gondii infection. Clin Microbiol Rev 1998;11:569-88.

71. Suzuki Y, Orellana MA, Schreiber RD, Remington JS. Interferon-gamma: the major mediator of resistance against Toxoplasma gondii. Science 1988;240:516-8.

72. Dubensky TW Jr, Liu MA, Ulmer JB. Delivery systems for gene-based vaccines. Mol Med 2000;6:723-32.

73. Bureau MF, Naimi S, Torero Ibad R, et al. Intramuscular plasmid DNA electroporation: biodistribution and degradation. Biochim Biophys Acta 2004;1676:138-48.

74. Greenland JR, Letvin NL. Chemical adjuvants for plasmid DNA vaccines. Vaccine 2007;25:3731-41.

75. Montomoli E, Piccirella S, Khadang B, Mennitto E, Camerini R, De Rosa A. Current adjuvants and new perspectives in vaccine formulation. Expert Rev Vaccines 2011; 10:1053-61.

76. Khosroshahi KH, Ghaffarifar F, Sharifi Z, et al. Comparing the effect of IL-12 genetic adjuvant and alum non-genetic adjuvant on the efficiency of the cocktail DNA vaccine containing plasmids encoding SAG-1 and ROP-2 of Toxoplasma gondii. Parasitol Res 2012;111:403-11.

77. Xue M, He S, Zhang J, Cui Y, Yao Y, Wang H. Comparison of cholera toxin A2/B and murine interleukin-12 as adjuvants of Toxoplasma multi-antigenic SAG1-ROP2 DNA vaccine. Exp Parasitol 2008;119:352-7.

78. Liu Q, Wang F, Wang G, et al. Toxoplasma gondii: immune response and protective efficacy induced by ROP16/GRA7 multicomponent DNA vaccine with a genetic adjuvant B7-2. Hum Vaccin Immunother 2014;10:184-91.

79. Wang PY, Yuan ZG, Petersen E, et al. Protective efficacy of a Toxoplasma gondii rhoptry protein 13 plasmid DNA vaccine in mice. Clin Vaccine Immunol 2012;19:1916-20.

80. Dooms H, Abbas AK. Control of CD4+ T-cell memory by cytokines and costimulators. Immunol Rev 2006;211:23-38.

81. Melchionda F, Fry TJ, Milliron MJ, McKirdy MA, Tagaya Y, Mackall CL. Adjuvant IL-7 or IL-15 overcomes immunodominance and improves survival of the CD8+ memory cell pool. J Clin Invest 2005;115:1177-87.

82. Li ZY, Chen J, Petersen E, et al. Synergy of mIL-21 and mIL-15 in enhancing DNA vaccine efficacy against acute and chronic Toxoplasma gondii infection in mice. Vaccine 2014;32:3058-65.
of Toxoplasma rhoptries. Nat Rev Microbiol 2008;6:79-88.
84. Bradley PJ, Ward C, Cheng SJ, et al. Proteomic analysis of rhoptry organelles reveals many novel constituents for host-parasite interactions in Toxoplasma gondii. J Biol Chem 2005;280:34245-58.
85. Liu Q, Li FC, Zhou CX, Zhu XQ. Research advances in interactions related to Toxoplasma gondii microneme proteins. Exp Parasitol 2017;176:89-98.
86. Brossier F, David Sibley L. Toxoplasma gondii: microneme protein MIC2. Int J Biochem Cell Biol 2005;37:2266-72.
87. Shirotta H, Klinman DM. Recent progress concerning CpG DNA and its use as a vaccine adjuvant. Expert Rev Vaccines 2014;13:299-312.
88. Sinha VR, Trehan A. Biodegradable microspheres for protein delivery. J Control Release 2003;90:261-80.
89. Jain S, O’Hagan DT, Singh M. The long-term potential of biodegradable poly(lactide-co-glycolide) microparticles as the next-generation vaccine adjuvant. Expert Rev Vaccines 2011;10:1731-42.
90. Xu Y, Zhang NZ, Wang M, et al. A long-lasting protective immunity against chronic toxoplasmosis in mice induced by recombinant rhoptry proteins encapsulated in poly(lactide-co-glycolide) microparticles. Parasitol Res 2015;114:4195-203.
91. Nabi H, Rashid I, Ahmad N, et al. Induction of specific humoral immune response in mice immunized with ROP18 nanospheres from Toxoplasma gondii. Parasitol Res 2017;116:359-70.
92. Chuang SC, Ko JC, Chen CP, Du JT, Yang CD. Encapsulation of chimeric protein rSAG1/2 into poly(lactide-co-glycolide) microparticles induces long-term protective immunity against Toxoplasma gondii in mice. Exp Parasitol 2013;134:430-7.
93. Flower DR, Macdonald IK, Ramakrishnan K, Davies MN, Doytchinova IA. Computer aided selection of candidate vaccine antigens. Immunome Res 2010;6 Suppl 2:S1.
94. Romano P, Giugno R, Pulvirenti A. Tools and collaborative environments for bioinformatics research. Brief Bioinform 2011;12:549-61.
95. Wang Y, Wang G, Cai J, Yin H. Review on the identification and role of Toxoplasma gondii antigenic epitopes. Parasitol Res 2016;115:459-68.
96. Zhou J, Wang L, Lu G, et al. Epitope analysis and protection by a ROP19 DNA vaccine against Toxoplasma gondii. Parasite 2016;23:17.
97. Cao A, Liu Y, Wang J, et al. Toxoplasma gondii: vaccination with a DNA vaccine encoding T- and B-cell epitopes of SAG1, GRA2, GRA7 and ROP16 elicits protection against acute toxoplasmosis in mice. Vaccine 2015;33:6757-62.
98. Cong H, Gu QM, Yin HE, et al. Multi-epitope DNA vaccine linked to the A2/B subunit of cholera toxin protect mice against Toxoplasma gondii. Vaccine 2008;26:3913-21.
99. Cong H, Yuan Q, Zhao Q, et al. Comparative efficacy of a multi-epitope DNA vaccine via intranasal, peroral, and intramuscular delivery against lethal Toxoplasma gondii infection in mice. Parasit Vectors 2014;7:145.
100. Yin H, Zhao L, Wang T, Zhou H, He S, Cong H. A Toxoplasma gondii vaccine encoding multistage antigens in conjunction with ubiquitin confers protective immunity to BALB/c mice against parasite infection. Parasit Vectors 2015;8:498.
101. Alexander J, Jebbari H, Bluethmann H, Satoskar A, Roberts CW. Immunological control of Toxoplasma gondii and appropriate vaccine design. Curr Top Microbiol Immunol 1996;219:183-95.